Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1967 5
1968 2
1969 2
1971 1
1972 2
1973 2
1974 2
1975 2
1977 1
1979 1
1983 2
1984 1
1985 1
1986 1
1987 1
1988 1
1990 1
1991 1
2015 1
2017 1
2019 1
2020 5
2021 8
2022 8
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.
Baldini C, Danlos FX, Varga A, Texier M, Halse H, Mouraud S, Cassard L, Champiat S, Signolle N, Vuagnat P, Martin-Romano P, Michot JM, Bahleda R, Gazzah A, Boselli L, Bredel D, Grivel J, Mohamed-Djalim C, Escriou G, Grynszpan L, Bigorgne A, Rafie S, Abbassi A, Ribrag V, Postel-Vinay S, Hollebecque A, Susini S, Farhane S, Lacroix L, Parpaleix A, Laghouati S, Zitvogel L, Adam J, Chaput N, Soria JC, Massard C, Marabelle A. Baldini C, et al. Among authors: vuagnat p. J Exp Clin Cancer Res. 2022 Jul 7;41(1):217. doi: 10.1186/s13046-022-02423-0. J Exp Clin Cancer Res. 2022. PMID: 35794623 Free PMC article. Clinical Trial.
Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program.
de Moura A, Vuagnat P, Renouf B, Pierga JY, Loirat D, Vaflard P, Lafayolle de la Bruyère C, Chaumard-Billotey N, Hajjaji N, Ladoire S, Dabakuyo S, Patsouris A, Frenel JS, Nicolai V, Alexandre M, Dohollou N, Grenier J, Bourien H, Bidard FC. de Moura A, et al. Among authors: vuagnat p. Sci Rep. 2023 Aug 18;13(1):13427. doi: 10.1038/s41598-023-40569-9. Sci Rep. 2023. PMID: 37596388 Free PMC article.
PALLIA 10 score in phase I cancer studies.
Ouali K, Mateus C, Laparra A, Martin Romano P, Sampetrean A, Vuagnat P, Varga A, Champiat S, Verlingue L, Geraud A, Marabelle A, Hollebecque A, Gazzah A, Bahleda R, Postel Vinay S, Michot JM, Bernard-Tessier A, Bayle A, Ribrag V, Soria JC, Scotte F, Massard C, Pavliuc E, Baldini C. Ouali K, et al. Among authors: vuagnat p. BMJ Support Palliat Care. 2022 Aug 30:bmjspcare-2022-003601. doi: 10.1136/spcare-2022-003601. Online ahead of print. BMJ Support Palliat Care. 2022. PMID: 36041820
Characteristics and Outcome of SARS-CoV-2 Infection in Cancer Patients.
Basse C, Diakite S, Servois V, Frelaut M, Noret A, Bellesoeur A, Moreau P, Massiani MA, Bouyer AS, Vuagnat P, Malak S, Bidard FC, Vanjak D, Kriegel I, Burnod A, Bilger G, Ramtohul T, Dhonneur G, Bouleuc C, Cassoux N; Institut Curie COVID Group,; Paoletti X, Bozec L, Cottu P. Basse C, et al. Among authors: vuagnat p. JNCI Cancer Spectr. 2021 Jan 6;5(1):pkaa090. doi: 10.1093/jncics/pkaa090. eCollection 2021 Feb. JNCI Cancer Spectr. 2021. PMID: 33604509 Free PMC article.
Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study.
Alhenc-Gelas M, Cabel L, Berger F, Delaloge S, Frenel JS, Levy C, Firmin N, Ladoire S, Desmoulins I, Heudel PE, Dalenc F, Loirat D, Dubot C, Vuagnat P, Deluche E, Mokdad-Adi M, Patsouris A, Annic J, Djerroudi L, Lavigne M, Pierga JY, Coppo P, Bidard FC. Alhenc-Gelas M, et al. Among authors: vuagnat p. Breast Cancer Res. 2021 Jan 19;23(1):9. doi: 10.1186/s13058-021-01386-y. Breast Cancer Res. 2021. PMID: 33468209 Free PMC article.
Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers.
Nebot-Bral L, Hollebecque A, Yurchenko AA, de Forceville L, Danjou M, Jouniaux JM, Rosa RCA, Pouvelle C, Aoufouchi S, Vuagnat P, Smolenschi C, Colomba E, Leary A, Marabelle A, Scoazec JY, Cassard L, Nikolaev S, Chaput N, Kannouche P. Nebot-Bral L, et al. Among authors: vuagnat p. J Immunother Cancer. 2022 Jul;10(7):e005059. doi: 10.1136/jitc-2022-005059. J Immunother Cancer. 2022. PMID: 35896284 Free PMC article.
Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies.
Baldini C, Martin Romano P, Voisin AL, Danlos FX, Champiat S, Laghouati S, Kfoury M, Vincent H, Postel-Vinay S, Varga A, Vuagnat P, Ribrag V, Mezquita L, Besse B, Hollebecque A, Lambotte O, Michot JM, Soria JC, Massard C, Marabelle A. Baldini C, et al. Among authors: vuagnat p. Eur J Cancer. 2020 Apr;129:71-79. doi: 10.1016/j.ejca.2020.01.013. Epub 2020 Mar 3. Eur J Cancer. 2020. PMID: 32143106
56 results